<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Clinical Neurosciences</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/ED2AC24B-32F5-4FED-A2F5-807D057416E4"><gtr:id>ED2AC24B-32F5-4FED-A2F5-807D057416E4</gtr:id><gtr:firstName>Sybil</gtr:firstName><gtr:surname>Stacpoole</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800487"><gtr:id>0D03788D-9CF0-4151-80ED-540F72F5D931</gtr:id><gtr:title>Generation of Human Oligodendrocytes from Embryonic Stem Cells - an Experimental Tool and Potential Therapy for Multiple</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0800487</gtr:grantReference><gtr:abstractText>Multiple sclerosis is a disease that initially damages the insulating coat of nerves in the brain and spinal cord. This coating is called myelin, and the cells that make it are termed oligodendrocytes. Without the coating, the nerves conduct very slowly, producing clinical symptoms such as paralysis or blindness. In the commonest form of multiple sclerosis, termed relapsing-remitting, the myelin sheath is initially repaired and the symptoms resolve. Over time, the patient?s ability to repair the damage fails, leading to neuronal death and persistent disability. 

My aim is to generate oligodendrocytes from human embryonic stem cells, which have the potential to give rise to any human cell. The challenge is to direct them to become oligodendrocytes, rather than any other cell type. I aim to achieve this through exposure of the stem cells to various combinations of growth factors; additionally, I may use a virus to introduce genes that are important in oligodendrocyte development. I then plan to study the factors involved in the maturation of these early oligodendrocytes into oligodendrocytes that make the myelin coat. Finally, I will transplant these oligodendrocytes into a mouse model of multiple sclerosis, to test their efficacy and safety in repairing the damage.</gtr:abstractText><gtr:technicalSummary>Multiple sclerosis (MS) is the commonest cause of acquired neurological disability in young adults. Treatments of MS have two aims: to prevent (disease modifying) and to repair damage that has already occurred. Although some advances in treatment to reduce relapse rate (RR) have been made in the last decade, little has been achieved in terms of definitive treatments for prevention or repair of fixed disability and disease progression. The lack of such therapies represents a substantial gap in the treatment of MS. Thus there is a requirement for strategies that promote remyelination and prevent axonal loss. Pathological and experimental studies suggest that these processes are tightly linked, and that remyelination will both restore structure and protect axons. There is, therefore, a need for a supply of human neural stem cells (NSCs) and oligodendrocyte precursors (OPCs) for biological characterisation and as a source of exogenous myelinogenic or promyelinating cells. 

A serious impediment to the development of remyelination therapies is the inability to generate sufficient numbers of human NSCs and OPCs from foetal and adult derived tissue using existing protocols. Human embryonic stem cells (hESCs), by contrast, on account of their responsiveness to morphogenetic cues, offer a potentially unlimited supply of NSCs / OPCs for biological and functional characterisation. My host laboratory has established an excellent experimental platform with the recent finding of scaleable derivation of hES-NSCs - using completely defined conditions. I propose to extend these studies to specifically generate large numbers of enriched human oligodendrocyte lineage cells by adopting developmental based insights around morphogenetic signalling cues and maturation factors and / or ectopic expression of key transcriptional regulators underlying oligodendrocyte specification (Olig2 / Nkx2.2). FACS based enrichment along with mitogenic stimulation of OPCs will be used to expand oligodendrocyte committed cells. I will then examine the in vitro behaviour of human OPCs and their differentiated progeny, as well as study their functional remyelinating capacity (in collaboration) in two experimental in vivo models of demyelination; focal model of demyelination (gliotoxin-irradiation) and a mouse model of chronic MS displaying demyelination and chronic axonal loss.</gtr:technicalSummary><gtr:fund><gtr:end>2011-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>204982</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Veterinary Medicine</gtr:department><gtr:description>Electrophysiology</gtr:description><gtr:id>2E5B1BE8-75B5-4F2D-A13E-4C0D9CB240A2</gtr:id><gtr:impact>This collaboration has contributed to two publications thus far.</gtr:impact><gtr:outcomeId>Xv2XKrB191k-1</gtr:outcomeId><gtr:partnerContribution>Electrophysiology</gtr:partnerContribution><gtr:piContribution>A very productive collaboration enabling investigation of the electophysiological properties of human ES-derived neural cells.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Departmental Presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C2A11917-FEA5-48C4-A14F-7CBB3C61F6CD</gtr:id><gtr:impact>I was invited to give a presentation on laboratory science research in MS repair strategies to a group of clinicians and associated health care professionals. This prompted some stimulating discussions around the role of the clinician in research (laboratory versus clinical trials).

Perhaps some increased awareness amongst clinical (non-research active) staff about the road from basic laboratory studies towards clinical trials and new treatments for patients.</gtr:impact><gtr:outcomeId>DojZsYTRcQu</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MS patient group meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>8AEF4754-CA75-4F6E-A0F1-F9D02E4064E1</gtr:id><gtr:impact>I was asked to give a presentation to a patient group in Norfolk, on an 'introduction to MS'. This stimulated an interesting discussion on the role of stem cell therapies in MS and plentiful questions from the patients.

I received generous feedback and requests to give a similar talk to a group of occupational and physio-therapists at a later date.</gtr:impact><gtr:outcomeId>h2jEHhE9oZa</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Graduate Society Conference, Jesus College Cambridge</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>10488BD0-79E3-4A55-9DF1-5C3E884D4183</gtr:id><gtr:impact>Presentation of my work to graduate students across all disciplines at the newly instituted Jesus College, Cambridge Graduates' Conference. I have given both oral and poster presentations, and was fortunate to receive the prize for best overall poster presentation in 2011.

This was a useful experience, presenting to an audience outside of the stem cell and multiple sclerosis field, and also to non-scientists. The presentation was enthusiastically received and it was helpful to discuss ethical and social aspects as well.</gtr:impact><gtr:outcomeId>A47A9A65ADA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2008,2009,2010,2011,2012</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>850</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Keystone Symposia Scholarship- Multiple Sclerosis Meeting</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>44D92BD2-1306-43F8-AB7E-7629CF293986</gtr:id><gtr:outcomeId>pACyTLMbFZN0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain Travel Grant</gtr:description><gtr:end>2013-02-02</gtr:end><gtr:fundingOrg>Guarantors of Brain</gtr:fundingOrg><gtr:id>6672F413-D5C1-4A43-A13D-109C994FA7B9</gtr:id><gtr:outcomeId>GpWfEeTLTKT</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Isabelle Bouhon Fund</gtr:department><gtr:description>Isabelle Bouhon Travel Scholarship</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>29EF4631-5EB3-4C72-AF5F-2FC812630182</gtr:id><gtr:outcomeId>WSek8hwEZvm</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Research Travel Grant</gtr:description><gtr:end>2011-02-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>0C290AA3-1CA5-430A-A19F-9CBF27AAF676</gtr:id><gtr:outcomeId>smgaeQnVDaw</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>800</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Brain Travel Grant</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>Guarantors of Brain</gtr:fundingOrg><gtr:id>8C2AC7A2-3081-4DFC-A7F2-721A0D85685F</gtr:id><gtr:outcomeId>NWsAqkiAjsA0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Rosemary Anne Price Award</gtr:description><gtr:end>2011-06-02</gtr:end><gtr:fundingOrg>Multiple Sclerosis Society</gtr:fundingOrg><gtr:id>827C7019-BF7D-4553-A40B-09500FDE6656</gtr:id><gtr:outcomeId>bHqMLMR2JsN</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>700</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Keystone Symposia Scholarship- Stem Cells Meeting</gtr:description><gtr:end>2010-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>F7CE8438-82A8-4B3A-BAC6-3D3ECA3079CC</gtr:id><gtr:outcomeId>aJHqnpqZTAt0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Raymond and Beverly Sackler Studentship</gtr:description><gtr:end>2011-09-02</gtr:end><gtr:fundingOrg>Raymond and Beverly Sackler Foundation</gtr:fundingOrg><gtr:id>76494105-A442-4F83-A02D-5FC80965DB35</gtr:id><gtr:outcomeId>Z2mXriCRory0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2008-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Isabelle Bouhon Fund</gtr:department><gtr:description>Isabelle Bouhon Young Investigator Award</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>59175D11-148A-48E7-BB12-4B60BA464C69</gtr:id><gtr:outcomeId>UmM5FtrivvX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>550</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Research Travel Grant</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>F096CD63-B536-4145-A534-73ED268B8C02</gtr:id><gtr:outcomeId>LqDVAiHrb1r</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1860</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>EG Fearnsides Fund</gtr:department><gtr:description>EG Fearnsides Travel Scholarship</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>EC82B049-5184-4769-86B6-4E35413824C7</gtr:id><gtr:outcomeId>dnTV58K1JJY</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Doctoral Research Travel Grant</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>0407520A-C74E-4E47-B304-915B71CF599B</gtr:id><gtr:outcomeId>HJk4LUacRbt</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>EG Fearnsides Travel Scholarship</gtr:description><gtr:end>2012-01-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>F06274DC-6BF4-45FC-AA4A-F2B506C07505</gtr:id><gtr:outcomeId>RfFreGqZfpF</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>EG Fearnsides Fund</gtr:department><gtr:description>EG Fearnsides Travel Scholarhip</gtr:description><gtr:end>2009-01-02</gtr:end><gtr:fundingOrg>University of Cambridge</gtr:fundingOrg><gtr:id>235728BA-EA45-4014-BD78-13621983B650</gtr:id><gtr:outcomeId>UPfocq8CsSi</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2D2EA5E3-D820-4FBA-9026-E41A140B94AF</gtr:id><gtr:title>Derivation of neural precursor cells from human ES cells at 3% O(2) is efficient, enhances survival and presents no barrier to regional specification and functional differentiation.</gtr:title><gtr:parentPublicationTitle>Cell death and differentiation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f045bf196326e3cba2157dc8deb0fa7"><gtr:id>0f045bf196326e3cba2157dc8deb0fa7</gtr:id><gtr:otherNames>Stacpoole SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1350-9047</gtr:issn><gtr:outcomeId>d29D5fS2kgW</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2FD26F16-6515-49FC-A570-2B303A51B709</gtr:id><gtr:title>Neural precursor cells cultured at physiologically relevant oxygen tensions have a survival advantage following transplantation.</gtr:title><gtr:parentPublicationTitle>Stem cells translational medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f045bf196326e3cba2157dc8deb0fa7"><gtr:id>0f045bf196326e3cba2157dc8deb0fa7</gtr:id><gtr:otherNames>Stacpoole SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2157-6564</gtr:issn><gtr:outcomeId>pm_14264_24_23677643</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A615A89F-AD63-401A-87C0-E952186B45B0</gtr:id><gtr:title>Efficient derivation of NPCs, spinal motor neurons and midbrain dopaminergic neurons from hESCs at 3% oxygen.</gtr:title><gtr:parentPublicationTitle>Nature protocols</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f045bf196326e3cba2157dc8deb0fa7"><gtr:id>0f045bf196326e3cba2157dc8deb0fa7</gtr:id><gtr:otherNames>Stacpoole SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1750-2799</gtr:issn><gtr:outcomeId>cZjFkGDFtzK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8BCCFB13-943F-4396-BA04-6AA50303A149</gtr:id><gtr:title>High yields of oligodendrocyte lineage cells from human embryonic stem cells at physiological oxygen tensions for evaluation of translational biology.</gtr:title><gtr:parentPublicationTitle>Stem cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f045bf196326e3cba2157dc8deb0fa7"><gtr:id>0f045bf196326e3cba2157dc8deb0fa7</gtr:id><gtr:otherNames>Stacpoole SR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2213-6711</gtr:issn><gtr:outcomeId>doi_14264_013_09_006</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800487</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>